Aerosol Deposition

Aerosolized medications play an important role in the management of most respiratory and some systemic conditions; access to peripheral lung regions is vital for effective drug delivery. Therefore, it is important to establish the effect of high frequency chest compression (HFCC)/high frequency chest wall oscillation (HFCWO) therapy on the pattern and extent of aerosol deposition in the lungs.

  1. Chambers C, Klous D, Nantel N, King M, Newhouse M. Does high-frequency chest compression (HFCC) during aerosol therapy affect lung deposition? Am J Respir Crit Care Med 1998; 157(suppl 3):A131.
    To assess the effects of high frequency chest compression (HFCC) on aerosol delivery to the lung, 10 normal subjects inhaled 99m Technetium-labeled Human Serum Albumin (HSA) aerosol alternately with and without HFCC. Study data suggest that, in normal subjects, 1) aerosol delivery is unimpaired by HFCC and 2) deposition to the lower respiratory tract is improved just short of significance.
  2. Perry GV, Stites SW, Peddicord T, Cox G, McMillian C. Effect of high frequency chest wall oscillation on the central and peripheral distribution of aerosolized DTPA as compared to standard chest physiotherapy in cystic fibrosis. Am J Respir Care Med 1999; 159(suppl 3):A686.
    This crossover study compared deposition of aerosolized technetium 99m diethylene triamine penta-acidic acid (DTPA) administered during high-frequency chest wall oscillation (HFCWO) therapy versus after standard chest physiotherapy (CPT) in seven cystic fibrosis (CF) patients with moderate to severe lung disease. Aerosol administration combined with HFCWO showed greater but non-significant deposition in central lung regions.
  3. Stites SW, Perry GV, Peddicord T, Cox G, McMillan C, Becker B. Effect of High-Frequency Chest Wall Oscillation on the Central and Peripheral Distribution of Aerosolized DTPA as Compared to Standard Chest Phyisotherapy in Cystic Fibrosis. Chest 2006; 129:712-717.
    This crossover evaluation compared the distribution of aerosolized (99m) Tc diethylene triamine penta-acetic acid (DTPA) administered simultaneously with high frequency chest wall oscillation (HFCWO) therapy with DTPA after chest physiotherapy (CPT). Subjects included ten cystic fibrosis (CF) patients (ages 22 to 38 years) with moderate-to-severe obstructive disease. The central to peripheral deposition ratio (C/P ratio) of each lung was analyzed in each study group. Use of HFCWO in combination with aerosolized DTPA did not result in increased central deposition or reduced peripheral distribution as compared with aerosolized DTPA administered after CPT.

The information provided on this website is not medical advice and does not substitute for the advice provided by a medical professional. The inCourage® System is only available upon a physician's order. Information provided throughout this website is intended for educational purposes only and should not be considered as medical or reimbursement advice.

Always consult a physician if you have health concerns and call 911 for a medical emergency. RespirTech's Customer Care professionals are available to respond to any questions you may have about the inCourage® Airway Clearance System.

Please call 800.793.1261 (Toll Free) or 651.379.8999 during business hours (8:00 a.m. to 5:00 p.m. CST, Monday through Friday), or you can leave a message after hours and we'll return your call the next business day.